A groundbreaking annual injection designed to protect against HIV has successfully passed its first safety trial, bringing new hope for long-term prevention.The drug, Lenacapavir, prevents the virus ...

Rabies is a deadly disease that spreads through animal bites, mostly from dogs. Experts warn that just getting a vaccine may not be enough—some cases need rabies immunoglobulin (RIG) for protection., ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...